Konrad Wiśniewski

Dr. Konrad Wiśniewski

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 1997 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
BKB. C. Kieseier
B. C. Kieseier
KWKonrad Wiśniewski
Konrad Wiśniewski
HGH. H. Goebel
H. H. Goebel

1 October 2000 in neurogenetics
Verified
Journal Article
Closed access
PDF file
NZN. A. Zhong
N. A. Zhong
DMD. N. Moroziewicz
D. N. Moroziewicz
WJWeiqiang Ju
Weiqiang Ju
KWKonrad Wiśniewski
Konrad Wiśniewski
AJA. Jurkiewicz
A. Jurkiewicz
WBW. T. Brown
W. T. Brown

28 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KWKonrad Wiśniewski
Konrad Wiśniewski
BCBarbara Choromańska
Barbara Choromańska
Mateusz MaciejczykMateusz Maciejczyk
Mateusz Maciejczyk
JDJacek Dadan
Jacek Dadan
Piotr MyśliwiecPiotr Myśliwiec
Piotr Myśliwiec
Obesity is a multifactorial metabolic disease characterized by chronic low-grade inflammation, extracellular matrix (ECM) dysfunction, and systemic metabolic dysregulation. Matrix metalloproteinases (MMPs), especially MMP-2 and MMP-9, are key regulators of ECM remodeling and inflammation in obesity. This narrative review aimed to synthesize and critically discuss current evidence on the effects of bariatric surgery and pharmacological therapies, including GLP-1 and dual GLP-1/GIP receptor agonists, on MMP activity and metabolic outcomes. Literature from PubMed and Scopus and Web of Science (2015–2024) was analyzed, focusing on studies evaluating MMPs, inflammation, and metabolic parameters. Bariatric surgery consistently reduces MMP-9 levels and normalizes MMP-2 activity, contributing to improved ECM integrity, reduced inflammation, and enhanced insulin sensitivity. Pharmacological therapies achieve substantial weight loss and glycemic control, but evidence regarding their direct effects on MMP activity remains limited. This review highlights bariatric surgery as the most effective strategy for modulating obesity-related MMP dysregulation and emphasizes the need for further research into the mechanistic effects of modern pharmacotherapy on ECM remodeling.

28 June 2008 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
EJE. C. Jenkins
E. C. Jenkins
CDC. J. Duncan
C. J. Duncan
CWC. E. Wright
C. E. Wright
FGFlavio Giordano
Flavio Giordano
LWL. Wilbur
L. Wilbur
WBW. T. Brown
W. T. Brown

15 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
KWKonrad Wiśniewski
Konrad Wiśniewski
BCBarbara Choromańska
Barbara Choromańska
Mateusz MaciejczykMateusz Maciejczyk
Mateusz Maciejczyk
JDJacek Dadan
Jacek Dadan
Piotr MyśliwiecPiotr Myśliwiec
Piotr Myśliwiec
Obesity is a multifactorial metabolic disease characterized by chronic low-grade inflammation, extracellular matrix (ECM) dysfunction, and systemic metabolic dysregulation. Matrix metalloproteinases (MMPs), especially MMP-2 and MMP-9, are key regulators of ECM remodeling and inflammation in obesity. This narrative review aimed to synthesize current evidence on the effects of bariatric surgery and pharmacological therapies, including GLP-1 and dual GLP-1/GIP receptor agonists, on MMP activity and metabolic outcomes. Literature from PubMed and Scopus (2015–2024) was analyzed, focusing on studies evaluating MMPs, inflammation, and metabolic parameters. Bariatric surgery consistently reduces MMP-9 levels and normalizes MMP-2 activity, contributing to improved ECM integrity, reduced inflammation, and enhanced insulin sensitivity. Pharmacological therapies achieve substantial weight loss and glycemic control but evidence regarding their direct effects on MMP activity remains limited. This review highlights bariatric surgery as the most effective strategy for modulating obesity-related MMP dysregulation and emphasizes the need for further research into the mechanistic effects of modern pharmacotherapy on ECM remodeling.

Verified
Journal Article
Open access
PDF file
KWKonrad Wiśniewski
Konrad Wiśniewski
BCBarbara Choromańska
Barbara Choromańska
Mateusz MaciejczykMateusz Maciejczyk
Mateusz Maciejczyk
ATAlan Tkaczuk
Alan Tkaczuk
AKAndrzej Kupisz
Andrzej Kupisz
Piotr MyśliwiecPiotr Myśliwiec
Piotr Myśliwiec
Adipose tissue expansion in obesity is accompanied by extracellular matrix (ECM) remodeling, regulated by matrix metalloproteinases (MMPs). Visceral adipose tissue (VAT) is metabolically more active than subcutaneous adipose tissue (SAT). However, depot-specific differences in proteolytic activity and protein glycooxidation remain incompletely characterized. In this case–control study, we assessed the activity of six matrix metalloproteinases (MMP-1, -2, -7, -9, -11, and -13) using a fluorescence resonance energy transfer (FRET) assay and quantified advanced glycation- and glycooxidation-related markers in paired VAT, SAT, and plasma samples obtained from 40 patients with obesity and 21 non-obese controls. The activities of all assessed MMPs were greater in patients with obesity than in the control group (p < 0.01 for all MMPs). Direct tissue-compartment comparisons showed that MMP activity and glycooxidation-related markers were most pronounced in VAT, with markedly higher values in obese individuals compared with controls. In VAT of obese individuals, median MMP activity was approximately 50–60% higher compared with controls. Amyloid cross-β-structure, vesperlysine, and pentosidine were significantly elevated in VAT in obesity, whereas plasma levels were markedly lower and showed limited group differences. No significant differences were observed between obese participants with and without metabolic syndrome. Obesity is associated with a depot-specific molecular profile characterized by enhanced proteolytic and glycooxidative activity predominantly within visceral adipose tissue. These findings highlight the importance of tissue-compartment-specific assessment in obesity.